10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: Influence of age and concomitant antiepileptic drugs

Therapeutic Drug Monitoring

Volumn 27, Issue 2, 2005, Pages 199-204

  Armijo, Juan A ^a   Vega Gil, Noelia ^a   Shushtarian, Mehrdad ^a   Adín, Javier ^a   Herranz, José L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

10 hydroxycarbazepine; Antiepileptic drugs; Concentration to dose ratio; Epilepsy; Monohydroxylated derivative; Oxcarbazepine; Patient age; Pharmacokinetic interactions; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CHILD; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGING; ANTICONVULSANTS; CARBAMAZEPINE; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 16244420126     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000155342.93489.fd     Document Type: Article

References (30)

1. Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):37-46.
2. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001;21:904-919.
3. Bang LM, Goa KL. Oxcarbazepine: a review of its use in children with epilepsy. Pediatr Drugs. 2003;5:557-573.
4. McLean MJ. Oxcarbazepine: mechanism of action. In: Levy RH. Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 451-458.
5. Bialer M. Oxcarbazepine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 459-465.
6. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of Oxcarbazepine. Clin Pharmacokinet. 2003;42:1023-1042.
7. Novartis Pharmaceuticals Corporation. Trileptal (oxcarbazepine) prescribing information (online). Available at: http://www.novartis.com/product/ pi/pdf/trileptal.pdf. Accessed June 15, 2004.
8. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol. 1994;47:161-167.
9. Pippenger CE. Pediatric clinical pharmacology of antiepileptic drugs: an especial consideration. In: Pippenger CE, Penry JK, Kutt H, eds. Antiepileptic Drugs: Quantitative Analysis and interpretation. New York: Raven Press, 1978, pp 315-319.
10. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther. 1999;66:547-553.
11. Albani F, Riva R, Baruzzi A. Oxcarbazepine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 466-469.
12. Sillampaa ML. Carbamazepine and oxcarbazepine. In: Wyllie E, ed. The Treatment of Epilepsy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001, pp 821-842.
13. Arnoldussen W, Hulsman J, Rentmeester T. Interaction between oxcarbazepine and phenytoin. Epilepsia. 1993;34(Suppl 6):37. (abstract)
14. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994;37:27-32.
15. Bares G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597-1607.
16. Tartara A, Galimberri CA, Manni R. et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol. 1993;36:366-368.
17. Sallas WM, Milosavljev S, D'Souza J, et al. Pharniacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther. 2003;74:138-149.
18. Hossain M, Sallas W, Gasparini M, et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology. 1999;52(Suppl 2):525. (abstract)
19. Stroink H, Tang KT, van Parys JAP, et al. Steady-state pharmacokinetics of oxcarbazepine in children. Epilepsia. 1998;39(Suppl 6):48. (abstract)
20. Arnoldussen W, Hulsman J, Rentmeester T. The interaction of valproate and clobazam on the metabolism of oxcarbazepine. Epilepsia. 1993; 34(Suppl 2):160. (abstract)
21. Hulsman JA, Rentmeester TW, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin Pharmacol Ther. 1995;58:383-389.
22. Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharm Drug Dispos. 1990;11:365-370.
23. Van Parys JAP, Meijer JWA, Segers JP. Dose-concentration proportionality in epileptic patients stabilized on oxcarbazepine: effects of comedication. Epilepsia. 1991;32(Suppl 1):70. (abstract)
24. May TW, Rambeck B, Salke-Kellermann A. Fluctuations of 10-hydroxycarbazepine during the day in epileptic patients. Acta Neurol Scand. 1996; 93:393-397.
25. Pariente-Khayat A, Tran A, Vauzelle-Kervuroedan F, et al. Pharmacokinetics of oxcarbazepine as add-on therapy in epileptic children. Epilepsia. 1994;35(Suppl 8):119. (abstract)
26. Dulac O, D'Souza J, Motte J. Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy. Ann Neurol. 2001;50(Suppl 1):104. (abstract)
27. Van Heiningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther. 1991;50:410-419.
28. Fraser AD, MacNeil W, Isner AF, et al. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit. 1995;17: 174-178.
29. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224-227.
30. Augusteijn R, van Parys JAP. Oxcarbazepine (Trileptal, OXC): dose-concentration relationship in patients with epilepsy. Acta Neurol Scand. 1990;82(Suppl 133):37. (abstract)